New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia

AIDS

Volumn 18, Issue 17, 2004, Pages 2243-2252

  Capoulade Métay, Corinne ^a   Ma, Liying ^a   Truong, Lien X ^d   Dudoit, Yasmine ^a   Versmisse, Pierre ^b   Nguyen, Ngai V ^d   Nguyen, Marie ^e   Scott Algara, Daniel ^b   Barré Sinoussi, Françoise ^b   Debré, Patrice ^a   Bismuth, Georges ^c   Pancino, Gianfranco ^b   Theodorou, Ioannis ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

^c INSTITUT COCHIN   (France)

^d PASTEUR INSTITUTE   (Viet Nam)

^e INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

Cambodia; CCR5; Chemokine; HIV 1 infection; Polymorphisms; Vietnam

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

AFRICA; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; GENE DELETION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION SENSITIVITY; INTRAVENOUS DRUG ABUSE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; SOUTHEAST ASIA;

CAMBODIA; CELL LINE; CHEMOKINES, CC; DNA, VIRAL; GENES, VIRAL; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MUTATION; POLYMORPHISM, GENETIC; RANTES; RECEPTORS, CCR5; SUBSTANCE-RELATED DISORDERS; VIETNAM;

EID: 10244253855     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200411190-00004     Document Type: Article

References (44)

1. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. International Union of Pharmacology XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
2. Samson M, Labbe O., Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996, 35:3362-3367.
3. Gong W, Howard OM, Turpin JA, Grimm MC, Ueda H, Gray PW, et al. Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication. J Biol Chem 1998, 273:4289-4292.
4. Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 1999, 274:17478-17483.
5. Detheux M, Standker L, Vakili J, Munch J, Forssmann U, Adermann K, et al. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med 2000, 192:1501-1508.
6. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181.
7. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996, 382:722-725.
8. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
9. Meyer L, Magierowska M, Hubert JB, Rouzioux C, Deveau C, Sanson F, et al. Early protective effect of CCR5δ32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO study group. AIDS 1997, 11:F73-F78.
10. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5δ32. The SEROCO study group. Lancet 1997, 349:1219-1224.
11. Libert F, Cochaux P, Beckman G, Samson M, Aksenova M, Cao A, et al. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998, 7:399-406.
12. Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, Robb ML, et al. Epidemiologic and biologic characterization of a cohort of human immunodefiency virus type 1 highly exposed, persistently seronegative female sex workers in Northern Thailand. J Infect Dis 1999, 179:59-67.
13. Magierowska M, Lepage V, Truong Xuan L, Nguyen Thi Hoang L, Guillotel M, Issafras H, et al. Novel variant of the CCR5 gene in a Vietnamese population. Microb Infect 1999, 2:123-124.
14. Truong Xuan L, Luong TT, Scoft-Algara D, Versmisse P, David A, Perez-Bercoff D, et al. CD4 cell and CD8 cell-mediated resistance to HIV-1 infection in exposed uninfected intravascular drug users in Vietnam. AIDS 2003, 17:1425-1434.
15. Yang C, Li M, Limpakarnjanarat K, Young NL, Hodge T, Butera ST, et al. Polymorphisms in the CCR5 coding and noncoding regions among HIV type-1 exposed, persistently seronegative female sex-workers from Thailand. AIDS Res Hum Retroviruses 2003, 19:661-665.
16. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HAF, et al. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, Northern Thailand. AIDS Res Hum Retroviruses 2001, 17:719-734.
17. Blanpain C, Lee B, Tackoen M, Puffer B, Boom A, Libert F, et al. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 2000, 96:1638-1645.
18. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997, 61:1261-1267.
19. Shioda T, Nakayama EE, Tanaka Y, Xin X, Liu H, Kawana-Tachikawa A, et al. Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J Virol 2001, 75:3462-3468.
20. Ansari-Lari A, Liu X-M, Metzkler ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nat Genet 1997, 16:221-222.
21. Zheng B-J, Zhao X-Y, Zhu N-S, Chan C-P, Wong K-H, Chan KCW, et al. Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. AIDS 2002, 16:2480-2482.
22. Quillent C, Oberlin E, Braun J, Rousset D, Conzalez-Canali C, Métais P, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351:14-18.
23. Follezou JY, Lan NY, Lien TX, Lafon ME, Tram LT, Hung PV, et al. Clinical and biological characteristics of human immunodeficiency virus-infected and uninfected intravascular drug users in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 1999, 61:420-424.
24. Nguyen M, Nouhin J, Ly N, Ing R, Phoung V, Barre-Sinoussi F, et al. In vitro susceptibility to HIV-1 infection of peripheral blood mononuclear cells of seronegative partners of HIV-1 infected individuals in Cambodia. Second IAS Conference on HIV Treatment and Pathogenesis. Paris, July 2003 [abstract 386].
25. Combadiere C, Ahuja SK, Tiffany HL, Murphy PM. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1α, MIP-1β, and RANTES. J Leukoc Biol 1996, 60:147-152.
26. Sol N, Ferchal F, Braun J, Pleskoff O, Treboute C, Artsart I, et al. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. J Virol 1997, 71:8237-8244.
27. Merat R, Raoul H, Leste-Lasserre T, Sonigo P, Pancino C. Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. J Virol 1999, 73:5698-5706.
28. Petersen DC, Kotze MJ, Zeier MD, Grimwood A, Pretorius D, Vardas E, et al. Novel mutations identified using a comprehensive CCR5-denaturing gradient gel electrophoresis assay. AIDS 2001, 15:171-177.
29. Zhou N, Luo Z, Hall JW, Luo J, Han X, Huang Z. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Eur J Immunol 2000, 30:164-173.
30. Carrington M, Dean M, Martin MP, O'Brien SJ. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999, 8:1939-1945.
31. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM for the Multicenter AIDS Cohort Study. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998, 352:866-870.
32. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997, 16:100-103.
33. 2adrenoceptor. EMBO 1997, 16:6737-6747.
34. Govaerts C, Bondue A, Springael J-Y, Olivella M, Deupi X, Le Poul E, et al. Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J Biol Chem 2003, 278:1892-1903.
35. Meng EC, Bourne HR. Receptor activation: what does the rhodopsin structure tell us? Trends Pharmacol Sci 2001, 22:587-593.
36. Blanpain C, Lee B, Vakili J, Doranz BJ, Covaerts C, Migeotte I, et al. Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 1999, 274:18902-18908.
37. Genoud S, Kajumo F, Cuo Y, Thompson D, Dragic T. CCR5-mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains. J Virol 1999, 73:1645-1648.
38. Lin Y-L, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA 2002, 99:15590-15595.
39. Fear WR, Kesson AM, Naif H, Lynch CW, Cunningham AL. Differential tropism and chemokine receptor expression of human immunodeficiency virus type 1 in neonatal monocytes, monocyte-derived macrophages, and placental macrophages. J Virol 1998, 72:1334-1344.
40. Naif HM, Li S, Alali M, Sloane A, Wu L, Kelly M, et al. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998, 72:830-836.
41. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol 1998, 72:4962-4969.
42. Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, Peden KWC, et al. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J Immunol 1998, 161:3103-3113.
43. Pedroza-Martins L, Gurney KB, Torbett BE, Uittenbogaart CH. Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level. J Virol 1998, 72:9441-9452.
44. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864.